DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note released on Saturday morning. The firm issued a hold rating on the stock.

Several other analysts have also weighed in on DBVT. HC Wainwright raised their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and issued a $25.00 target price on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Trading Down 0.3 %

Shares of DBVT stock opened at $3.89 on Friday. The company has a market capitalization of $75.08 million, a P/E ratio of -0.86 and a beta of 0.66. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $10.70. The stock has a 50 day moving average of $3.43 and a two-hundred day moving average of $4.15.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.